Riken
Amoy Diagnostics PLC Panel Gets Approval in Japan as CDx for Retevmo in Non-Small Cell Lung Cancer
Oncologists in Japan can now use the AmoyDx Pan Lung Cancer PCR Panel to identify patients with RET fusions that make them eligible for treatment with the Eli Lilly drug.
Amoy Diagnostics CDx Gets Japanese Approval to ID NSCLC Patients Eligible for Tepmetko
The Japanese Ministry of Health, Labor, and Welfare has approved AmoyDx's PLC Panel for use in identifying NSCLC patients with MET exon 14 skipping alterations.
AmoyDx PCR Panel Receives Japanese Approval as CDx for Non-Small Cell Lung Cancer Therapies
The Japanese MHLW approved the real-time PCR-based test as a CDx to detect four driver genes for nine associated NSCLC targeted therapies.
Sysmex, Riken Innovation Form Diagnostic Development Alliance
The partners aim to develop new diagnostic technologies and businesses, with a focus on diseases for which there are no established diagnostic methods.